Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis (VILLENDO)

A Randomized, Double-blind, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Two Different Doses of Vilaprisan (BAY1002670) Versus Placebo in Women With Symptomatic Endometriosis

The primary objective of this study was to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis.

The secondary objective of this study was to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis.

With the implementation of protocol version 4.0 dated 11-Dec-2018, no new subjects were enrolled. The objectives above cannot be reached as only limited data is available from subjects recruited before the temporary pause.

Study Overview

• Status: Terminated
• Conditions: Endometriosis
• Intervention / Treatment: Drug: Vilaprisan (BAY1002670); Drug: Matching Placebo

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 2

Contacts and Locations

Study Locations

• Austria
  • Villach, Austria, 9500
    • KABEG Landeskrankenhaus Villach
  • Wien, Austria, 1090
    • Universitätsklinikum AKH Wien
  • Oberösterreich
    • Linz, Oberösterreich, Austria, 4020
      • Kepler Universitätsklinikum Campus IV
  • Steiermark
    • Graz, Steiermark, Austria, 8036
      • Medizinische Universitat Graz
• Canada
  • Ontario
    • Kingston, Ontario, Canada, K7L 2V7
      • Queen's University
    • Ottawa, Ontario, Canada, K1H 7W9
      • Ottawa Hospital-Riverside Campus
  • Quebec
    • Montreal, Quebec, Canada, H4P 2S4
      • Clinique ovo
• Czechia
  • Brno, Czechia, 602 00
    • Gynekologie MEDA s.r.o.
  • Plzen, Czechia, 326 00
    • Gyncare MUDr. Michael Svec s.r.o.
• Finland
  • Helsinki, Finland, 00510
    • VL-Medi Oy
  • Pori, Finland, 28500
    • Satakunnan Keskussairaala
• Italy
  • Veneto
    • Verona, Veneto, Italy, 37126
      • A.O.U.I. Verona
• Japan
  • Kumamoto, Japan, 861-8520
    • Japanese Red Cross Kumamoto Hospital
  • Toyama, Japan, 930-8550
    • Toyama Prefectural Central Hospital
  • Hokkaido
    • Sapporo, Hokkaido, Japan, 060-0031
      • Tokeidai Memorial Clinic
  • Ishikawa
    • Kanazawa, Ishikawa, Japan, 920-8530
      • Ishikawa Prefectural Central Hospital
• Poland
  • Lublin, Poland, 20-093
    • Centrum Medyczne Chodzki
• United States
  • District of Columbia
    • Washington, District of Columbia, United States, 20036
      • Office of Dr. James A. Simon, MD
  • Florida
    • Boynton Beach, Florida, United States, 33435
      • Helix Biomedics, LLC
    • Jacksonville, Florida, United States, 32256
      • Solutions Through Advanced Research, Inc.
  • Louisiana
    • Metairie, Louisiana, United States, 70001
      • Southern Clinical Research Associates LLC
  • North Carolina
    • Morehead City, North Carolina, United States, 28557
      • Unified Women's Clinical Research - Morehead City
    • Winston-Salem, North Carolina, United States, 27103
      • Unified Women's Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Signed and dated informed consent
• Pre-menopausal women 18 years (inclusive) and above at the time of Visit 1
• Women with endometriosis confirmed by laparoscopy or laparotomy OR diagnosed based on imaging
• Moderate to severe endometriosis-associated pelvic pain (EAPP)
• Adherence to screening period diary entries
• Willingness to use only standardized pain medication if needed
• Good general health (except for findings related to endometriosis)
• Normal or clinically insignificant cervical cytology not requiring further follow-up
• An endometrial biopsy performed at the screening phase without significant histological disorder
• Use of an acceptable non-hormonal method of contraception
• Willingness / ability to comply with electronic diary entry for the duration of study participation

Exclusion Criteria:

• Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation before Visit 1)
• Hypersensitivity to any ingredient of the study treatments
• Laboratory values outside the inclusion range before randomization, and considered clinically relevant
• Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug including elevated liver enzymes
• Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
• Undiagnosed abnormal genital bleeding
• Abuse of alcohol, drugs, or medicines (e.g. laxatives) as evaluated by the investigator
• Use of other treatments that might interfere with the conduct of the study or the interpretation of the results
• Endometriosis-specific treatments for symptom relief except rescue pain medication according to protocol
• Simultaneous participation in another clinical trial with investigational medicinal product(s). Participation in another trial prior to study entry that might have an impact on the study objectives, at the discretion of the investigator
• Inability to cooperate with the study procedures for any reason
• Previous assignment to treatment (e.g. randomization) during this study (allowing previously randomized subjects to be re-included into the study may lead to bias)
• Hypersensitivity to any ingredient of standardized pain medication
• Wish for pregnancy during the study
• Regular use of pain medication due to other underlying diseases
• Non-responsiveness of EAPP to GnRH-a (Gonadotropin-releasing hormone agonists)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Vilaprisan (BAY1002670) 2 mg; Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg	Drug: Vilaprisan (BAY1002670); Intake orally, once daily
Experimental: Vilaprisan (BAY1002670) 4 mg; Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg	Drug: Vilaprisan (BAY1002670); Intake orally, once daily
Placebo Comparator: Placebo group; Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1	Drug: Matching Placebo; Intake orally, once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Worst Pelvic Pain (Measured on a Numerical Rating Scale [NRS], Recorded in the Daily Endometriosis Symptom Diary [ESD])	Pain intensity was assessed on 11-point (0-10) NRS by ESD item 1. In ESD item 1, participants were asked to rate the worst pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. Mean 'worst pelvic pain' was calculated as the sum of the participant's daily assessments of the ESD item 1 ("worst pain" during the last 24 hours) during a study period divided by number of days with pain assessment in that study period. This was summarized by study period. No inferential statistical analysis was performed.	Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Worst Pelvic Pain (Measured on a Numerical Rating Scale [NRS], Recorded in the Daily Endometriosis Symptom Diary [ESD]) on Days With/Without Vaginal Bleeding	Pain intensity was assessed on 11-point (0-10) NRS by ESD item 1. In ESD item 1, participants were asked to rate the worst pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. Mean 'worst pelvic pain' on bleeding/non-bleeding days was calculated as the sum of the participant's daily assessments of the ESD item 1 ("worst pain" during the last 24 hours) on bleedings/non-bleeding days during a study period divided by number of bleeding/non-bleeding days with pain assessment in that study period. This was summarized by study period. No inferential statistical analysis was performed.	Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)
Mean Number of Tablets of Rescue Pain Medication 1 (Ibuprofen 200 mg) Taken Daily for Endometriosis-associated Pelvic Pain (EAPP)	Mean number of tablets of rescue pain medication 1 (Ibuprofen 200 mg) taken daily for EAPP was calculated as the sum of the tablets taken for EAPP during a study period divided by the number of days in that study period. This was summarized by study period. No inferential statistical analysis was performed.	Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)
Mean Number of Tablets of Rescue Pain Medication 2 (Tramadol 50 mg) Taken Daily for Endometriosis-associated Pelvic Pain (EAPP)	Mean number of tablets of rescue pain medication 2 (Tramadol 50 mg) taken daily for EAPP was calculated as the sum of the tablets taken for EAPP during a study period divided by the number of days in that study period. This was summarized by study period. No inferential statistical analysis was performed.	Screening period (up to a maximum of 75 days) + treatment period (up to a maximum of 168 days)
The Number of Participants With Treatment Emergent Adverse Events (TEAEs)	An adverse event (AE) is any untoward medical occurrence (i.e. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. TEAE is defined as AE that is observed or reported after the first administration of study drug or if it starts before the first administration of study drug and the intensity/grade worsens on treatment) in this study.	Up to 6 months
Number of Participants With Clinical Significant Abnormal Endometrial Histology Findings	Number of participants with endometrial histology findings, e.g. hyperplasia, malignant neoplasm or endometrial polyps	Up to 6 months
Number of Participants With Clinical Significant Abnormal Ultrasound Examinations	Ultrasound examinations (evaluated for efficacy and safety) will be performed by a qualified expert in performing gynecologic ultrasound exams. If possible, the same examiner should conduct all examinations of a subject throughout the study and the same ultrasound machine (per site) should be used throughout the study. Preferably the safety evaluation should be performed by transvaginal ultrasound (TVU). However, if deemed appropriate, transabdominal or transrectal ultrasound examinations can be performed instead. The chosen method should be used consistently throughout the study.	Up to 6 months
Number of Participants With Clinical Significant Abnormal Bone Mineral Density Measurements	A Dual-energy X-ray absorptiometry (DEXA) scan of the lumbar spine (lumbar anterior-posterior, L1-L4) and the hip/femoral neck were performed.	Up to 6 months
Number of Participants With Clinical Significant Abnormal Laboratory Values	Clinical laboratory values including the values of hematology, general chemistry, urinalysis, coagulation, hormones, immunology and vitamins.	Up to 6 months

Collaborators and Investigators

• Sponsor: Bayer

Publications and helpful links

Helpful Links

• Click here to find results for studies related to Bayer products
• Click here to find information about studies related to Bayer Healthcare products conducted in Europe

Study record dates

Study Major Dates

• Study Start (Actual): July 4, 2018
• Primary Completion (Actual): March 18, 2019
• Study Completion (Actual): November 26, 2020

Study Registration Dates

• First Submitted: June 19, 2018
• First Submitted That Met QC Criteria: June 19, 2018
• First Posted (Actual): June 29, 2018

Study Record Updates

• Last Update Posted (Actual): May 4, 2022
• Last Update Submitted That Met QC Criteria: April 13, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endometriosis
• Other Study ID Numbers: 15792; 2013-004768-72 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No